drugset / Trial / NCT04586985

Safety, Tolerability and Pharmacokinetics of FTX-6058

NCT04586985 ↗

Phase 1 Completed 109 enrolled Fulcrum Therapeutics
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a study to evaluate the safety, tolerability and pharmacokinetics of FTX-6058 in healthy adult subjects and adult subjects with sickle cell disease (SCD).

Timeline

Start
2020-10-26
Primary completion
2022-11-15
Completion
2022-11-15

Outcome

Met primary endpoint

release “the interim results from this clinical trial of FTX-6058, which demonstrated compelling results across all primary, secondary, and exploratory endpoints included in this study.” fulcrumtx.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 3 mg Oral
Subject Pociredir Small molecule 2 mg Oral
Subject Pociredir Small molecule 4 mg Oral
Subject Pociredir Small molecule 6 mg Oral
Subject Pociredir Small molecule 10 mg Oral
Subject Pociredir Small molecule 20 mg Oral
Subject Pociredir Small molecule 30 mg Oral
Subject Pociredir Small molecule 40 mg Oral
Subject Pociredir Small molecule 60 mg Oral
Subject Pociredir Small molecule 90 mg Oral

Indications